ClinicalTrials.gg
RecruitingNCT07231679Updated Oct 7, 2026

A Study to Investigate IGT-303 in Healthy Volunteers and Participants With Chronic Kidney Disease

A Phase 1/2 interventional study of IGT-303 and Placebo in Healthy Volunteers and Chronic Kidney Disease, sponsored by Ingenia Therapeutics INC. Recruiting at 13 sites in 4 countries. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-07.

Sponsored by Ingenia Therapeutics INC · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year later.
Updated Oct 7, 2026First sites in South Korea and United StatesPrimary completion moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
94
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 102 studies in Renal Insufficiency, Chronic with a site in Australia — 19 open to participants now, 29 under way, 16 of them phase 3. Renal Insufficiency, Chronic · Australia.

Planned enrollment
73rd of 92
94 · median 347
Started
2025
with 10 others
Phase 1/2
3 of 102
2 open now
Primary completion
2026-12
later than 8 of 28 live
Registered
96th of 102
by date

Among the 102 studies in Renal Insufficiency, Chronic with a site in Australia, this one is the 73rd largest by planned enrollment of the 92 interventional ones that give a count, is one of 11 that started in 2025, is one of 3 in phase 1/2, reaches primary completion later than 8 of the 28 other live ones, and was the 96th registered.

Renal Insufficiency, Chronic

3,098 studies on the registry are indexed under Renal Insufficiency, Chronic; 700 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

19 of the 102 studies in Renal Insufficiency, Chronic with a site in Australia are open now. Recruiting first, the newest first:

13 more — sign in →

All 19 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 434 Renal Insufficiency, Chronic studies recruiting now, 245 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 43 take children under 18; 80 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 102 studies in Renal Insufficiency, Chronic with a site in Australia, or all of them as a file.
02

Study summary

The goal of this clinical trial is to observe the safety of IGT-303 in healthy volunteers and participants with Chronic Kidney Disease. The main question it aims to answer is:

Is IGT-303 safe as a single dose or multiple dose regimen when applied under the skin (subcutaneously (SC)) or to a vein (intravenously (IV)).

Researchers will compare IGT-303 against a placebo to see if IGT-303 is safe for use.

Participants will be assigned to either IGT-303 or placebo and assessed for safety and tolerability for the duration of the study.

03

Conditions studied

  • Healthy Volunteers
  • Chronic Kidney Disease
04

Who can participate

The criteria were revised on the registry on Oct 7, 2026. See what changed

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant 18-75 years of age, inclusive, at Screening;
  • Able to understand the key components of the study as described in the written document, and willing and able to provide written informed consent;
  • (BMI) within the range of 18.5 to 40 kg/m2 at Screening;
  • Have a diagnosis of chronic kidney disease stage 2-3b, resulting from Type 2 diabetic nephropathy;
  • UACR >30 mg/g, \<5000 mg/g at Screening;
  • If taking antihypertensive and/or antidiabetic medication, doses of medications must be stable for at least 90 days prior to Screening;
  • Stable . in the opinion of the Investigator, for at least 90 days prior to Screening;
  • \<9.0% at Screening;
  • Participants assigned male at birth (AMAB) will be either sterile or agree to use an approved method of from Screening until at least 5 half-lives plus 90 days after the last dose of study drug, or do not engage in sexual relations which carry a risk of pregnancy (does include abstinence), and agree to refrain from sperm donation and in vitro fertilization until 5 half-lives plus 90 days after the last dose of the study drug; Participants assigned female at birth (AFAB) must be of non- or agree to use two highly effective methods of conception from Screening until at least 5 half-lives plus 30 days after the last dose of study drug or do not engage in sexual relations which carry a risk of pregnancy (does include abstinence), and agree to refrain from egg donation and in vitro fertilization until 5 half-lives plus 30 days after the last dose of the study drug
  • In the opinion of the Investigator, is able to adhere to the requirements of the study, including required overnight stays in the research site;
  • For participants in Cohort 9 only, have a diagnosis of nonproliferative diabetic retinopathy

Exclusion criteria

Exclusion Criteria:

  • Known allergy to study medication or its components (non-medicinal ingredients) or a history of a severe allergic reaction to any drug or history of multiple food/drug allergies;
  • Use of cigarettes exceeding >5 cigarettes per week at time of Screening; social/casual cigarette use (≤5 per week) is permitted during the study, but participants must be willing to abstain during inpatient confinement;
  • Positive urine screen for drugs of abuse including tetrahydrocannabinol or has a positive breathalyzer test, at Screening or at Day -1;
  • Any illness or medical history that would impact safety or compliance with study requirements or impact ability to interpret study data
  • For participants in Cohort 9 only, presence of diabetic macular edema with anti-vascular endothelial growth factor (VEGF) treatment or vitreous hemorrhage.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
94 participants (estimated)

Study arms

  • Experimental
    IGT-303

    Part A: single ascending dose (SAD), 6 cohorts Part B: multiple ascending dose (MAD), 3 cohorts

    Drug: IGT-303

  • Placebo comparator
    Placebo

    Placebo (normal saline)

    Drug: Placebo

Interventions

  • DrugIGT-303

    IGT-303 administered via IV or SC

  • DrugPlacebo

    Saline

06

What researchers measure

Primary outcomes

  1. Adverse events (AEs), serious adverse events (SAEs), and treatment-emergent adverse events (TEAEs)

    The number and severity (by Grade) will be measured.

    Time frame: From Screening to Day 84.

Secondary outcomes

  1. PK Parameters of Intravenous (IV) and Subcutaneous (SC) IGT-303

    Maximum observed concentration (Cmax)

    Time frame: Day 1 to Day 84.

  2. PK Parameters of IV and SC IGT-303

    Observed time of maximum concentration (Tmax)

    Time frame: Day 1 to Day 84

  3. PK Parameters of IV and SC IGT-303

    Terminal exponential rate constant, determined using the linear least squares regression of the terminal phase of the log-serum concentration time profile (λz)

    Time frame: Day 1 to Day 84

  4. PK Parameters of IV and SC IGT-303

    Terminal exponential half-life, calculated as ln(2)/λz (T1/2)

    Time frame: Day 1 to Day 84

  5. PK parameters of IV and SC IGT-303

    Area under the concentration-time curve calculated using linear trapezoidal rule from time zero to time t, where t is the time of the last observed quantifiable concentration (AUC0-t)

    Time frame: Day 1 to Day 84

  6. PK parameters of IV and SC IGT-303

    Area under the concentration-time curve from time zero to infinity, defined as AUC0-t + Ct/λz (AUC0-∞)

    Time frame: Day 1 to Day 84

  7. PK parameters of IV and SC IGT-303

    Total clearance (CL), defined as dose/AUC0-∞

    Time frame: Day 1 to Day 84

  8. PK parameters of IV and SC IGT-303

    Terminal volume of distribution (Vz), defined as CL/λz

    Time frame: Day 1 to Day 84

  9. PK parameters of IV and SC IGT-303

    Absolute bioavailability (F), defined as the dose-corrected (AUC0-∞ SC) / (AUC0-∞ IV)

    Time frame: Day 1 to Day 84

07

Study locations

9 of 13 sites recruiting
  • Balboa Nephrology - Chula Vista
    Chula Vista, California 91910, United States
    Not yet recruiting
  • Clinical Research of Central Florida
    Lakeland, Florida 33805, United States
    Not yet recruiting
  • Piedmont HealthCare
    Statesville, North Carolina 28625, United States
    Not yet recruiting
  • Wilmington Health
    Wilmington, North Carolina 28412, United States
    Not yet recruiting
  • Nucleus Network
    Herston, Brisbane 4006, Australia
    Recruiting
  • Renal Research
    Gosford, New South Wales 2250, Australia
    Recruiting
  • Concord Repatriation General Hospital
    Sydney, New South Wales 2139, Australia
    Recruiting
  • University of the Sunshine Coast Clinical Trials-Southbank
    Morayfield, Queensland 4506, Australia
    Recruiting
  • University of the Sunshine Coast-Morayfield
    Morayfield, Queensland 4506, Australia
    Recruiting
  • Sunshine Hospital
    Saint Albans, Victoria 3021, Australia
    Recruiting
  • Pacific Clinical Research Network
    Takapuna, Auckland 0622, New Zealand
    Recruiting
  • Momentum Clinical Research
    Waikanae Beach, Kapiti Coast 5036, New Zealand
    Recruiting
  • Seoul National University Hospital
    Seoul, 03080, South Korea
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Dec 2026, 14 months after the start.

Of 22 phase 1/2 interventional studies under Renal Insufficiency, Chronic, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 55. This study's planned 14 months is below that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 7, 2026: primary completion Oct 2026 → Dec 2026 and completion Jan 2027 → Apr 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 13, 2025
First posted
Nov 17, 2025
StartActual
Oct 30, 2025
Primary completionEst.
Dec 2026was Oct 2026
CompletionEst.
Apr 2027was Jan 2027
Last update
Oct 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
9 sites added, 1 site removed — first sites in South Korea and United States
Show 9 added (4 United States, 4 Australia, 1 South Korea)
  • Balboa Nephrology - Chula Vista · Chula Vista, United States
  • Clinical Research of Central Florida · Lakeland, United States
  • Piedmont HealthCare · Statesville, United States
  • Wilmington Health · Wilmington, United States
  • Renal Research · Gosford, Australia
  • Concord Repatriation General Hospital · Sydney, Australia
  • University of the Sunshine Coast-Morayfield · Morayfield, Australia
  • Sunshine Hospital · Saint Albans, Australia
  • Seoul National University Hospital · Seoul, South Korea
Show 1 removed
  • University of Sunshine Coast-Morayfield · Morayfield, Australia
Oct 7, 2026
Primary completion
Oct 2026→Dec 2026
Oct 7, 2026
Study completion
Jan 2027→Apr 2027
Oct 7, 2026
Eligibility
1 inclusion criterion edited, 2 added
What changed in the criteria
Inclusion criteria
  • EditedUACR >30 mg/g, <5000 mg/g at Screening and Day -1;
  • AddedStable eGFR. in the opinion of the Investigator, for at least 90 days prior to Screening;
  • AddedHbA1C <9.0% at Screening;
Oct 7, 2026
Show all 1 update
  1. Oct 7, 2026
    9 sites added, 1 site removed — first sites in South Korea and United States
    Show 9 added (4 United States, 4 Australia, 1 South Korea)
    • Balboa Nephrology - Chula Vista · Chula Vista, United States
    • Clinical Research of Central Florida · Lakeland, United States
    • Piedmont HealthCare · Statesville, United States
    • Wilmington Health · Wilmington, United States
    • Renal Research · Gosford, Australia
    • Concord Repatriation General Hospital · Sydney, Australia
    • University of the Sunshine Coast-Morayfield · Morayfield, Australia
    • Sunshine Hospital · Saint Albans, Australia
    • Seoul National University Hospital · Seoul, South Korea
    Show 1 removed
    • University of Sunshine Coast-Morayfield · Morayfield, Australia
    Primary completion Oct 2026→Dec 2026
    Study completion Jan 2027→Apr 2027
    Eligibility 1 inclusion criterion edited, 2 added
    What changed in the criteria
    Inclusion criteria
    • EditedUACR >30 mg/g, <5000 mg/g at Screening and Day -1;
    • AddedStable eGFR. in the opinion of the Investigator, for at least 90 days prior to Screening;
    • AddedHbA1C <9.0% at Screening;
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07231679
Lead sponsor
Ingenia Therapeutics INC
Responsible party
Sponsor
First posted
Nov 17, 2025
Start date
Oct 30, 2025
Primary completion
Dec 2026 (estimated)
Completion
Apr 2027 (estimated)
Last update
Oct 7, 2026

Study contacts

Jennifer Curry, PharmD
Contact
jc@curryclinicalconsulting.com
317-726-9118
Jinsam You, PhD
Contact
jyou@ingeniatx.com
617-440-2518
Emma Trowbridge, MD
principal investigator · Nucleus Network

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion